Discovery of 3-(4-hydroxybenzyl)-1-(thiophen-2-yl)chromeno[2,3-c]pyrrol-9(2H)-one as a phosphodiesterase-5 inhibitor and its complex crystal structure
- 1 May 2014
- journal article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 89 (1) , 86-98
Abstract
No abstract availableKeywords
This publication has 60 references indexed in Scilit:
- Tadalafil as monotherapy and in combination regimens for the treatment of pulmonary arterial hypertensionTherapeutic Advances in Respiratory Disease, 2012
- Structure-Based Discovery of Highly Selective Phosphodiesterase-9A Inhibitors and Implications for Inhibitor DesignJournal of Medicinal Chemistry, 2012
- Targeting Phosphodiesterases in Anti-platelet Therapy2012
- Role of Ca 2+ /Calmodulin-Stimulated Cyclic Nucleotide Phosphodiesterase 1 in Mediating Cardiomyocyte HypertrophyCirculation Research, 2009
- Kinetic and Structural Studies of Phosphodiesterase-8A and Implication on the Inhibitor SelectivityBiochemistry, 2008
- An insight into the pharmacophores of phosphodiesterase-5 inhibitors from synthetic and crystal structural studiesBiochemical Pharmacology, 2008
- Conformational Variations of Both Phosphodiesterase-5 and Inhibitors Provide the Structural Basis for the Physiological Effects of Vardenafil and SildenafilMolecular Pharmacology, 2008
- Structural insight into substrate specificity of phosphodiesterase 10Proceedings of the National Academy of Sciences, 2007
- The Role of Cyclic Nucleotides in Axon Guidance2007
- [20] Processing of X-ray diffraction data collected in oscillation mode1997